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Abstract
Biofilms, sedimented microbial communities embedded in a biopolymer matrix cause vast
majority of human bacterial infections and many severe complications such as chronic
inflammatory diseases and cancer. Biofilms’ resistance to the host immunity and antibiotics
makes this kind of infection particularly intractable. Antimicrobial peptides (AMPs) are a ubiq-
uitous facet of innate immunity in animals. However, AMPs activity was studied mainly on
planktonic bacteria and little is known about their effects on biofilms. We studied structure
and anti-biofilm activity of AMP complex produced by the maggots of blowfly Calliphora
vicina living in environments extremely contaminated by biofilm-forming germs. The complex
exhibits strong cell killing and matrix destroying activity against human pathogenic antibiotic
resistant Escherichia coli, Staphylococcus aureus and Acinetobacter baumannii biofilms as
well as non-toxicity to human immune cells. The complex was found to contain AMPs from
defensin, cecropin, diptericin and proline-rich peptide families simultaneously expressed in
response to bacterial infection and encoded by hundreds mRNA isoforms. All the families
combine cell killing and matrix destruction mechanisms, but the ratio of these effects and
antibacterial activity spectrum are specific to each family. These molecules dramatically
extend the list of known anti-biofilm AMPs. However, pharmacological development of the
complex as a whole can provide significant advantages compared with a conventional one-
component approach. In particular, a similar level of activity against biofilm and planktonic
bacteria (MBEC/MIC ratio) provides the complex advantage over conventional antibiotics.
Available methods of the complex in situ and in vitro biosynthesis make this idea practicable.
Introduction
Bacteria exist in two basic life forms: planktonic form destined for bacteria proliferation and
biofilms enabling them to survive in adverse conditions. Biofilms, sedimented microbial
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communities embedded in a biopolymer matrix have come to particular prominence since
they cause main part of human bacterial infections and highly resistant to antibiotics and host
immunity (for review see [1–5]). Recent studies have found that bacterial biofilms play a role
in the onset and development of stomach [6], colorectal [7], colon [8], prostate [9], breast [10]
and lung [11] cancer. Thus, biofilms’ impact on the human life and death extends far beyond
the classic field of infectious pathology. This makes the search for new anti-biofilm drug candi-
dates especially relevant. Naturally occurring antimicrobial peptides (AMPs) are generally rec-
ognized as a prospective platform for antibacterial drugs development [12–16]. Although
virtually all studied to date multicellular animals use some form of AMPs to defend against
pathogens, their greatest diversity is found in insects. Classification, structural and functional
diversity and mechanism of action of insect AMPs are considered in review articles [17, 18].
Considerable attention was paid to insect AMPs as potential drugs [18–21]. However, thera-
peutic AMPs development meets a bunch of well-known obstacles [22–24]. Among other
things should be noted that the development focuses on the individual antimicrobial com-
pounds capable of stopping the infection when applied alone. This approach corresponds well
to the experience of conventional antibiotics development. In contrast, natural AMP-based
defense systems use complexes of active molecules rather than single molecule approach [25].
The benefits of multicomponent AMP systems for the host remain poorly understood
although the synergistic/potentiating actions among naturally co-occurring AMPs [26–29]
and the capacity to prevent resistance development in bacteria [30] were described in experi-
ments with various forms of planktonic bacteria.
This article analyses anti-biofilm activity of host AMP complex, which remains unexplored
though some individual AMPs under review [15, 31–33] demonstrated activity against bio-
films. Based on our previous work, we have chosen for experimental study naturally occurring
AMP complex isolated from the maggots of blowfly Calliphora vicina (Diptera, Calliphoridae)
and named here FLIP7 (abbreviation from Fly Larvae Immune Peptides 7). Like other mem-
bers of Calliphoridae family known in medicine as a "medicinal maggots” [34], C. vicina
maggots in response to bacterial infection immediately synthesize and accumulate in the
hemolymph four families of cationic AMPs: defensins, cecropins, diptericins and proline-rich
peptides [30, 35, 36]. The hemolymph also contains other immune response related com-
pounds including antiviral and antitumor peptides alloferons [37]. Calliphora defensin, as well
as defensins of other insects and vertebrates, is a peptide with a 3D structure containing α-
helix/β-sheet elements coordinated by 3 disulfide bridges and is predominantly active against
Gram-positive bacteria. Mode of insect defensins’ antibacterial activity comprises bacterial cell
wall disruption/permeabilization [17]. Calliphora cecropin is a linear amphipathic α-helical
peptide particularly active towards Gram-negative bacteria. All insect cecropins are known to
have pore forming and cell membrane permeabilizing activity [17]. Calliphora diptericins are
members of a glycine-rich AMP family selectively toxic to some Gram-negative Enterobacteria
like E. coli by means of cell wall disruption [38]. Calliphora proline-peptides [30, 36] belong to
the family of proline/arginine-rich AMPs, which is known to kill bacteria by interfering DNA
and/or protein synthesis [39].
Materials and methods
Insects
Experiments were performed with a laboratory colony of blue blowfly C. vicina originating
from St. Petersburg area (North-West of Russia) and characterized by stable larval diapause.
Breeding conditions were essentially the same as previously described [40]. To induce diapause
in the progeny, adult flies were kept under short day conditions (12L:12D). The larvae were
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fed by fresh beef at 12˚C, third instar larvae were transferred to 3˚C at the end of feeding
period, left there for 2 weeks to form diapause and then taken to the experiments.
C. vicina AMP complex preparation
The process of the complex preparation was the same as described [30]. Lyophilized live cul-
ture of E. coli M17 strain (Microgen, Russia) suspended in sterile distilled water was used to
induce an immune response in diapausing C. vicina larvae. The larvae were pricked with a nee-
dle previously dipped into the suspension containing 1010 bacterial cells/mL and were left
overnight at 25˚C. Their surface was then sterilized in 70% ethanol, washed with sterile dis-
tilled water and dried. Hemolymph (approximately 10 μl per animal) was collected in ice-cold
tubes through a cuticle puncture. Hemolymph samples were kept at -70˚C until use. Thawed
hemolymph was acidified with 0.1% trifluoroacetic acid (TFA) to a final concentration of
0.05% and insoluble particles were removed by centrifugation (30 min at 8000g at 4˚C). The
supernatant was applied to reversed-phase Sep-Pak C18 cartridges (Waters) stabilized by
0.05% TFA in the amount of 5 mL/g of sorbent. Highly hydrophilic compounds were removed
by cartridge washing with 0.05% TFA. Compounds absorbed in the cartridge were eluted with
50% acetonitrile solution acidified with 0.05% TFA, lyophilized (FreeZone, Labconco) and
stored at -70˚C. Prior to use, the lyophilized sample was dissolved in deionized water (50 mg/
mL), sterilized by filtration through a membrane with a pore size 0.22 μm (Milliex-GS, Milli-
pore) and frozen at -70˚C.
Antimicrobial peptides characterization
The complex AMPs were previously isolated and characterized by a combination of reversed
phase HPLC, MS and Edman degradation methods [25, 35]. In that work 1 mg of the lyophi-
lized compound was dissolved in deionized water and applied to Shimadzu LC20 Prominence
HPLC system equipped with analytical column C18 Vydac (4.6 × 250 mm, 5 μm, Grace), equil-
ibrated with 0.05% TFA. The column was eluted with a linear gradient of acetonitrile (ACN)
from 0 to 50% in acidified water (0.05% TFA) for 50 min. Chromatographic fractions were
automatically collected with 1 min intervals. The fractions’ optical densities were registered by
means of a UV detector at two fixed wavelengths 214 and 280 nm. The fractions were lyophi-
lized, dissolved in deionized water and tested against planktonic M. luteus A270 and E. coli
D31strains using the plate growth inhibition assay. Anti-biofilm activity of the fractions
against one-day biofilms formed by E. coli ATCC 25922 и S. aureus 203 was analyzed by TTC
and crystal violet assays as described below.
Mass spectrometry
The chromatographic fractions containing antibacterial materials were diluted in deionized
water to 100 μL volume. The molecular masses of the materials were determined by the Micro-
TOF ESI method on a MaXis chromato-mass spectrometer (Bruker Daltonik, Bremen, Ger-
many). Mass specters were registered using positive-ion mode in 50–1000 mass diapasons.
Capillary voltage was established at 4500 V, and 500 V at the end of the capillary. Dry gas was
applied at flow rate 4 L/min under temperature 180˚C. In-source collision-induced dissocia-
tion (ISCID) was turned on, and collision voltages up to 200 V were used. Mass spectrograms
were performed manually to take into account that all the peaks differ from the background
signal. Experimentally determined masses were compared with the previously published char-
acteristics of C. vicina individual AMPs.
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Transcriptome analysis
An immune response leading to the sharp activation of AMPs biosynthesis was induced in dia-
pausing larvae 1 week after the end of the feeding period in accordance with the procedure
described in the section “C. vicina AMP complex preparation”. After 18 hours, when the
AMPs titer reaches a maximum in the hemolymph [35], the larvae were frozen in liquid nitro-
gen and ground. Isolation of total RNA was performed using TRIzol1 Reagent according to
the manufacturer’s protocol (https://tools.thermofisher.com/content/sfs/manuals/trizol_
reagent.pdf). The resulting total RNA was used for cDNA synthesis using the Roche cDNA
synthesis system (https://lifescience.roche.com/shop/products/cdna-synthesis-system). cDNA
was sequenced on the device Ion Torrent and cDNA library was created using software Mira.
Search of antimicrobial peptide sequences in the cDNA library was done using Blast software
and previously published C. vicina AMPs as queries. Alignment method: compositional matrix
adjust [41]. In the analysis were used sequences with 70–100% similarity (P<0.001).
Antimicrobials
The following commercial preparations were used as reference antibiotics in the experiments:
meropenem trihydrate from carbopenems (AstraZeneca), third generation cephalosporin
sodium cefotaxime (Abolmed), naturally occurring polypeptide polymyxin B sulfate (Appli-
chem) and glycopeptide vancomycin (Kraspharma). The antibiotics were dissolved in sterile
deionized water in concentration 1 mg/ml, aliquoted in 0.05 ml volumes and kept at -70˚C
until use.
Bacteria
Escherichia coli ATCC 25922 and NCTC 13353 strains as well as a series of clinical strains of
Staphylococcus aureus and Acinetobacter baumannii have been used as model biofilm forming
bacteria. The annotated genome assembly of E. coli ATCC 25922 and NCTC 13353 strains are
available under the links http://www.ncbi.nlm.nih.gov/nuccore/CP009072 and http://www.
ebi.ac.uk/ena/data/view/ERS530434 respectively. A. baumannii 28 genome is sequenced and
deposited in Genbank (Acc.№NZ_MAFT00000000.1) and available under the link https://
www.ncbi.nlm.nih.gov/nuccore/NZ_MAFT00000000. The strain genome sequencing predicts
resistance to aminoglycosides, beta-lactams and chloramphenicol. The clinical strains origi-
nate from the surgery clinic of the Kirov Military Medical Academy (St. Petersburg, Russia),
except for the strains of A. baumannii 28 and S. aureus 203 originating from the collection of
Northwestern State Medical Mechnikov University and Institute of Experimental Medicine
(St. Petersburg, Russia), respectively. E. coli D31 and Micrococcus luteus A270 strains routinely
employed in insect AMP studies were obtained from the Institute of Genetics and Molecular
and Cellular Biology (France) and used for the complex AMPs characterization. Profiles of the
clinical strains’ antibiotic resistance were determined as recommended (National Committee
for Clinical Laboratory Standards, 2003. Performance Standards for Antimicrobial Disk Sus-
ceptibility Tests. Approved standard M2-A8. NCCLS, Wayne, PA). The strains were classified
as susceptible, intermediate or resistant to the antibiotic tested by disc diffusion method. To
test resistance profiles of A. baumannii strains the following antibiotics were used: amikacin,
gentamicin, imipenem, meropenem, cefepime, cefoperazone, cefotaxime, ceftazidime, cipro-
floxacin (Oxoid, Great Britain). The strain 143 was found resistant to all antibiotics tested
except amikacin, which was intermediately effective. The strain 149.2 demonstrated resistance
to cefoperazone, cefotaxime, ceftazidime, intermediate resistance to cefepime and sensitivity
to the rest of antibiotics. S. aureus profiles were tested against amikacin, penicillin, vancomy-
cin, gentamicin, doxycycline, azithromycin, clindamycin, chloramphenicol, netilmicin,
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oxacillin, cefazolin, ciprofloxacin, fusidic acid, linezolid (Oxoid, Great Britain). The strain 203
was found sensitive to all tested antibiotics while strain 73.1 showed resistance to azithromycin
only. Moreover, serial microdilution tests demonstrated sensitivity to polymyxin B in all A.
baumannii and E. coli strains used in experiments.
Antibacterial activity assays
Solid growth inhibition assay. Standard plate-growth inhibition assay was employed for
identification and relative quantification of the complex active compounds. The method was
essentially the same as the one previously described [30]. E. coli D31 and M. luteus A270 cul-
tures were grown in LB liquid nutrient medium (Invitrogen) for 18–20 hours at 37˚C. Sterile
Petri dishes (9 cm in diameter) were filled with 7.5 mL of LB medium supplemented with 12g/
L agarose (Invitrogen). 4 x 106 CFU/dish test microorganisms measured by OD were inocu-
lated into the warm medium. The analytes were dissolved in 20 μl of deionized sterile water
and 2 μl aliquot of the solution was applied onto a solid medium surface. The diameter of the
growth inhibition zone was measured after 24-hour incubation at 37˚C and the inhibition
zone area was calculated and used for relative quantification of the AMP anti-M. luteus and
anti-E. coli activity.
Liquid growth inhibition assay. The standard microdilution method was carried out for
MIC determination with LB broth (Invitrogen), as recommended (Clinical Laboratory Stan-
dards Institute, 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that
grow aerobically. Approved Standard, 10th edition, M07-A10. CLSI, Wayne, PA). Briefly, indi-
vidual wells of a 96-well tissue culture plate (Sarstedt, Newton, NC) containing 100 μl of liquid
nutrient medium LB (Invitrogen) with doubling antibiotic dilutions were inoculated with
approximately 5 x 105 CFU/mL of test bacteria. The initial inoculum was grown on the solid
LB agar nutritive medium (Invitrogen), individual colonies were picked up, transferred into
liquid medium (Luria broth base, 25 g/L) and incubated overnight at 37˚C. Microtiter plates
were incubated for 20 hours at 37˚C.
Biofilm formation
Preparation of 24-h old biofilm corresponds to the procedures outlined by Christensen et al.
[42]. In brief, bacteria were cultured in 5 ml of LB liquid nutrient medium (Invitrogen) for 18–
20 hours at 37˚C. Overnight cultures were adjusted 5x105 CFU/ml test microorganisms mea-
sured by OD. One hundred microliter aliquots of the diluted bacterial suspension were inocu-
lated into each well of a 96-well flat-bottomed polystyrene plate (Sarstedt AG & Co., Newton,
NC) and incubated in a humidified incubator for 24 h at 37˚C. The negative control was LB
liquid nutrient medium.
Crystal violet assay has been employed to visualize and quantify biofilm formation capacity
of bacteria as recommended [43]. Bacteria were incubated 24 h in the 96-well plates, washed
out of culture medium and stained by crystal violet as described in the section Biofilm eradica-
tion assay. Optical density in the well has been used as a measure of biofilm thickness. Each
experiment was performed in 8 replicates.
Biofilm microscopic visualization
Coverslip 24x24 mm (Thermo Fisher Scientific Gerhard Menzel B.V. & Co. KG, Braun-
schweig, Germany) was placed in each well of 6-well tissue culture microtitre plate (Falcon,
Becton Dickinson Labware, Franklin Lakes, NJ, USA). The wells were filled with 2.8 mL of
bacterial suspension prepared as mentioned above and the plates were incubated 24 hours at
37˚C. Then the 24-hour biofilms were washed three times with 3 mL of sterile physiological
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buffered saline (PBS) to remove unattached bacteria and filled with fresh culture medium
(control) or the medium supplemented with 4 mg/mL of FLIP7. The plates were incubated for
another 24 hours at 37˚C. Then coverslips were removed from the wells, washed in PBS, placed
on a glass slide upside down and photographed through a Leica DMI 2500 microscope (Leica
Microsystems GmbH, Wetzlar, Germany), Nomarski optics x 400 and x 1000.
TTC cell killing assay
We used colorimetric antimicrobial susceptibility test which can measure the antimicrobial
susceptibility of biofilmed bacteria [44]. This method uses trimethyl tetrazolium chloride
(TTC) as an indicator of viable bacteria and is comprised of the following steps: preparation of
a 24-h old biofilm, treatment with the antimicrobial agent, addition of 0.02% TTC and mea-
surement of TTC absorbance at 540 nm. Since reduction of TTC by viable bacteria produces
red formazan, bacterial growth inhibition can be measured quantitatively by colorimetric
absorbance at 540 nm. The 24-h biofilms in a 96-well tissue culture microtitre plates were
washed three times with 200 μL of sterile physiological buffered saline (PBS) solutions to
remove unattached bacteria and air-dried. Serial two-fold dilutions of antimicrobials were pre-
pared. 100 μL of each concentration was added to each corresponding well and plates were
incubated 24 h at 37˚C in a humidified incubator. After incubation, 11 μl of 0.2% TTC (Len-
reactive, Russia) was added to a final concentration of 0.02%. After 1 h incubation at 37˚C, the
OD540 was measured on the Epoch microplate reader (BioTek). The mean OD540 value of 48-h
biofilmed cells without treatment with the antimicrobial agent was set as the control. Each
experiment was performed in triplicate. Then, the minimum biofilm inhibitory concentration
(MBIC) was determined as the lowest concentration of drug that resulted in a mean % value
less than 100%.
Crystal violet biofilm eradication assay
Biofilm eradication assays were performed using a previously described method with some
modifications [43]. The 24-h biofilms in a 96-well tissue culture microtitre plates were washed
three times with 200 μL of sterile PBS solutions and air-dried. Serial two-fold dilutions of anti-
microbials were prepared. 100 μL of each concentration was added to each corresponding well
and plates were incubated 24 h at 37˚C. After the incubation, the waste media was removed
and plates were washed three times with 200 μL PBS solutions, air-dried and stained with crys-
tal violet 0.1% (in water) (Lenreactiv, Russia) for exactly 2 min. The stained biofilms were
washed three times with 200 μL PBS solutions, air-dried and solubilised with 200 μL 95% etha-
nol for 1 h. Then the biofilm cell-associated dye was measured at OD570 using the Epoch
reader (BioTek). Each experiment was performed in triplicate. The minimum biofilm eradica-
tion concentration (MBEC) was assessed with MBEC50 and MBEC90, which is the concentra-
tion of drugs decreasing crystal violet binding in preformed biofilms, by 50% and 90%,
respectively.
Cytotoxicity assay
Human mononuclear leukocytes (lymphocytes and monocytes) have been used as a model for
FLIP7 cytotoxicity assessment. The cells were isolated from donor venous blood by means of
BD Vacutainer1 CPT (BD Biosciences) as recommended by the manufacturer, and trans-
ferred to RPMI culture medium enriched with glutamine, 10% fetal calf serum and antibiotic
antimycotic solution A5955 (Sigma-Aldrich). Lyophilized FLIP7 was diluted in the culture
medium, passed through the filter 0.45 μm and introduced into the medium a final concentra-
tion 0.5, 5 and 10 mg/mL. Then, the number of lymphocytes and monocytes differentially
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stained with annexin V (apoptosis marker) and propidium iodide (PI, necrosis marker) was
counted using a standard flow cytometry Annexin-V-FITC binding assay according to the
manufacturer’s instructions (BioRad ANNEXIN V KIT). Analyses were performed by BD
FACSAria III flow cytometer (530/30nm and 616/23nm filters) with BD FACSDiva software.
The cells were divided into the following categories:
• Normal (undamaged) cells (annexin V and PI double negative)
• Apoptotic (annexin V positive)
• Necrotic (annexin V negative, PI positive)
Each experiment included 6 independent replications. Average numbers of apoptotic and
necrotic cells per 100 gated cells were used as a quantitative indicator of FLIP7 toxicity.
Statistical methods
MIC, MBIC and MBEC values (mean ± standard error) were calculated by means of the
Primer of Biostatistics software, version 4.03. Statistical significance of the differences was ana-
lyzed by ANOVA considering P values<0.05 as significant.
Results
Biofilm forming capacity of tested bacteria
To visualize and quantify the ability of bacteria to form biofilms, the standard crystal violet
staining method has been employed. All the studied bacteria were able to form detectable bio-
films on the plastic surface, but a one-day biofilm thickness measured in units of crystal violet
optical density varied from strain to strain (Table 1). Maximal ability to form biofilms was
detected in E. coli ATCC 25922 and S. aureus 203 strains.
Microscopic visualization of biofilm formation and FLIP7 anti-biofilm
effect
The biofilm formation was also analyzed by light microscopy using A. baumannii 28, E. coli
ATCC 25922 and S. aureus 203 strains, which demonstrated high biofilm formation capacity
in crystal violet assay. All three strains formed dense biofilms containing live bacteria attached
to the glass surface (Fig 1). The appearance of FLIP7 treated biofilms differed sharply from
Table 1. Biofilm formation capacity of tested bacteria (crystal violet assay).
Bacteria Strain characteristics Optical density A570 nm, units P* Biofilm formation capacity
Control 1 day biofilm
E. coli ATCC 25922 Antibiotic sensitive 0.1 ± 0.002 0.7 ± 0.05 <0.001 High
E. coli NCTC 13353 Beta-lactamase producing 0.1 ± 0.004 0.1 ± 0.03 0.17 Low
S. aureus 203 Antibiotic sensitive 0.1 ± 0.002 1.1 ± 0.08 <0.001 High
S. aureus 73.1 Azitromycin resistant 0.1 ± 0.01 0.3 ± 0.03 0.03 Intermediate
A. baumannii 28 Antibiotic multiresistant 0.1 ± 0.002 0.6 ± 0.04 <0.001 High
A. baumannii 143 Antibiotic multiresistant 0.1 ± 0.01 0.26 ± 0.03 0.02 Intermediate
A. baumannii 149.2 Antibiotic multiresistant 0.1 ± 0.01 0.8 ± 0.09 0.002 High
*P–statistical significance of differences in optical density compared to control wells without added bacteria. Each test consisted of 3 independent
measurements.
doi:10.1371/journal.pone.0173559.t001
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Fig 1. Photomicrographs of biofilms formed by three bacterial strains in normal conditions and in the
presence of FLIP7. A. baumannii 28, E. coli ATCC 25922 and S. aureus 203 biofilms grown as described in
Materials and Methods section were incubated 24 hours in the culture medium (control) or the medium
supplemented with 4 mg/mL of FLIP7 and photographed using Nomarski optics at 400-fold and 1000-fold
(inset) magnification. All three strains formed dense biofilms containing live bacteria attached to the glass
surface (control). At the same time, FLIP7 presence in the medium led to the destruction of the biofilm, in the
remains of which are visible mainly cells that have lost their characteristic shape.
doi:10.1371/journal.pone.0173559.g001
Antimicrobial peptides in the fighting of antibiotic resistant biofilms
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that of the normal state. Remains of biofilms turned into formless detritus and the few remain-
ing bacterial cells resembled the cells treated with membrane-acting peptides [45, 46].
The impact of FLIP7 and conventional antibiotics on the viability of
planktonic cultures and biofilms
Comparison of the sensitivity of bacteria living in planktonic and biofilm forms to FLIP7 and
reference antibiotics has been made by means of standard TTC cell viability assay (Table 2).
Reference antibiotics were selected for each strain based on its antibiotic resistance profile
described in Materials and Methods section. All tested materials demonstrated anti-biofilm
activity quantitatively characterized by MBIC90 value. However, MBIC90/MIC ratio demon-
strates the resistance growth variation depending on the biofilm-forming bacteria features. In
E.coli strains resistance to FLIP7 grew from 3.3 to 10.3 times (6.8 ± 3.5 in average) whereas
resistance to reference antibiotics increased 24–40 (31.4 ± 3.4) times. In S. aureus biofilms
FLIP7 resistance growth was even less significant: 0.9–2.3 times (1.6 ± 0.7) as compared to
planktonic forms while meropenem resistance growth varied in broad range from 3.6 to>167
times. Resistance in A. baumanii biofilms grew from 18 to 51 times (33 ± 9.64 in average) to
FLIP7 and 43 to 667 times to polymyxin B. Since both polymyxin B and FLIP7 active
Table 2. Planktonic and biofilm bacteria sensitivity to FLIP7 and reference antibiotics (TTC assay).
Strain Planktonic bacteria MIC, μg/mL Biofilm bacteria MBIC90, μg/mL P* MBIC90/ MIC ratio
E. coli ATCC 25922
FLIP7 500 ± 0.00 1667 ± 88 <0.001 3.3
Cefotaxime 0.125 ± 0.00 3 ± 0.7 0.005 24
Meropenem 0.03 ± 0.00 0.9 ± 0.3 <0.001 30
Polymyxin 0.5 ± 0.00 12.3 ± 0.3 <0.001 24.6
E. coli NCTC 13353
FLIP7 250 ± 0.00 2567 ± 617 0.02 10.3
Meropenem 0.06 ± 0.00 2.3 ± 0.9 0.073 38.3
Polymyxin 1.3 ± 0.3 52 ± 14 0.022 40.0
S. aureus 203
FLIP7 667 ± 167 1543 ± 137 0.015 2.3
Meropenem 0.03 ± 0.005 >5 >167
Vancomycin 0.5 ± 0.00 25± 13 0.134 50
S. aureus 73.1
FLIP7 8000 ± 0.00 7333 ± 167 0.016 0.9
Meropenem 0.08 ± 0.00 0.29 ± 0.08 0.06 3.6
A. baumannii 28
FLIP7 125 ± 0.00 6433 ± 1417 0.011 51
Polymyxin B 0.4 ± 0.1 267 ± 67 0.016 667
A. baumannii 143
FLIP7 125 ± 0.00 3767 ± 33 <0.001 30
Polymyxin B 0.25 ± 0.00 >20 >80
A. baumannii 149.2
FLIP7 416 ± 83 7600 ± 306 <0.001 18
Meropenem 0.5 ± 0.00 1.5 ± 0.06 <0.001 3
Polymyxin B 0.7 ± 0.2 30.3 ±6.2 0.009 43
*Each test consisted of 3 independent measurements
doi:10.1371/journal.pone.0173559.t002
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compounds belong to AMPs, this bacteria seems to form biofilms well adapted to AMPs attack
in contrast to E. coli and S. aureus. It is notable that beta-lactam antibiotic meropenem demon-
strated stronger anti-biofilm activity against A. baumannii and S. aureus 73.1 but not against
other bacteria.
FLIP7 and reference antibiotics comparative cell killing and biofilm
eradicating activities
Anti-biofilm activity of the materials was further studied by means of TTC and crystal violet
assays using E. coli ATCC 25922 and S. aureus 203 strains as models (Table 3). E. coli biofilms
demonstrated 6-time resistance growth to FLIP7 in comparison with planktonic culture
according to both cell viability TTC and biofilm eradicating crystal violet assays. Thus, these
two FLIP7 effects realized at the same concentration and with this point of view, they are
closely related. Cefotaxime and meropenem reduced biofilm thickness by 90% when applied
in a concentration 4 times greater than planktonic culture MIC, but it did not lead to bacteria
death. To kill 90% of bacteria it was necessary to increase their concentration in the 17–33
times. Polymyxin concentration destroying 90% of the bacteria in E. coli biofilm exceeded the
MIC of planktonic culture 50 times.
Experiment with S. aureus biofilm revealed even more remarkable difference between
FLIP7 and reference antibiotics. S. aureus biofilm resistance against FLIP7 in comparison with
planktonic culture grew less than 2 times according to both TTC and crystal violet assays. At
the same time the MBEC90 values of meropenem and vancomycin exceeded the maximum
definable level 167 and 83 times, respectively. Additionally, Table 3 contains MBEC50 values
demonstrating dramatic growth of S. aureus biofilm resistance to the reference antibiotics but
not to FLIP7.
Composition of FLIP7 antimicrobial peptides
Composition of FLIP7 AMPs was primarily characterized by combination of liquid chroma-
tography and solid growth inhibition assays (Fig 2). 1 mg of FLIP7 was fractionated by HPLC,
52 fractions collected with 1 min intervals were lyophilized and their antibacterial activities
were quantified through solid growth inhibition assay using planktonic cultures of Gram-
Table 3. FLIP7 and reference antibiotics effects on the E. coli ATCC 25922 and S. aureus 203 biofilms cell viability and thickness.
Planctonic Biofilm cells viability* Biofilm thickness*
Strains MIC* (TTC assay) (Cristal violet assay)
μg/mL MBIC90 MBIC90/ MBEC50 MBEC50/ MBEC90 MBEC90/
μg/mL MIC μg/mL MIC μg/mL MIC
E. coli
FLIP7 667 ± 167 4100 ± 208 6.15 817 ± 60 1.2 4083± 1543 6.1
Cefotaxime 0.125 ± 0.00 4.17 ± 0.83 33.4 0.14 ± 0.03 1.1 0.53 ± 0.04 4.24
Meropenem 0.06 ± 0.00 1 ± 0.00 16.7 0.14 ± 0.01 2.3 0.24± 0.0006 4.0
Polymyxin 0.5 ± 0.00 24.7 ± 0.3 49.4 9.4 ± 0.3 18.8 14.3 ± 1.1 28.6
S. aureus
FLIP7 500 ± 0.00 933 ± 17 1.9 590 ± 105 1.2 973 ± 15 1.9
Meropenem 0.03 ± 0.00 >5 >167 3.5 ± 0.8 116.7 >5 >167
Vancomycin 0.6 ± 0.00 >50 >83 17.5 ± 5.1 29.2 >50 >83
*Each test consisted of 3 independent measurements
doi:10.1371/journal.pone.0173559.t003
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negative E. coli D31 and Gram-positive M. luteus A270 bacteria embedded to solid agar
medium. The majority of anti-M. luteus activity was present in fractions 28 to 30, whereas
compounds active against E. coli were found in a broad range of fractions starting from 23 to
34. The active fractions distribution was essentially the same as described previously [30].
Anti-biofilm activity of the same chromatographic fractions was analyzed using combina-
tion of TTC and crystal violet assays (Table 4). Fractions 1–21 and 40–52 containing no anti-
bacterial activities against planktonic (solid growth inhibition assay) and biofilm (TTC, crystal
violet assays) bacteria are excluded from Table 4 for simplicity. Experiments with E. coli ATCC
25922 biofilm revealed evidential cell killing activity in fractions 26 and 28 to 33 and biofilm
eradicating activity in fractions 28 to 34, respectively. According to the solid growth inhibition
assays (Fig 2), in which planktonic bacteria were tested, all fractions can be divided into inac-
tive (no zone of inhibition) and active (the zone size varies depending on the activity of the
fraction). The optical density in inactive fractions 5–21, 37, 40–47 (n = 26) measured by TTC
and crystal violet assays was, respectively, 0.7 ± 0.016 AU540 nm (σ = 0.076) and 1.23 ± 0.045
AU570 nm (σ = 0.229). The active fractions include two subsets with respect to anti-biofilm
activity. Most of the anti-biofilm activity belongs to the range of fractions 28–33, in which the
cell viability and biofilm thickness reach the minimum level. Here the optical densities in TTC
and crystal violet assays in each fraction are far beyond 3 σ threshold for the mean value of
inactive fractions. Mean values of TTC (0.23 ± 0.067) and crystal violet (0.26 ± 0.047) optical
densities in these fractions are also significantly lower (P<0.001) in comparison with inactive
fractions. Highest cell killing activity (96% suppression compared to the mean value of inactive
fractions) belongs to the fraction 32 whereas highest biofilm eradicating activity (90%
Fig 2. C. vicina AMP complex chromatographic fractionation and anti-biofilm compounds
positioning. The complex was exposed to reversed phase HPLC and the resulting fractions antimicrobial
activity against E. coli D31 and M. luteus A270 strains was tested using solid growth inhibition assay as
explained in Materials and Methods section. The resulting fractions were used for mass spectrometry analysis
of the composition and antimicrobial activity of the components. Active fractions are marked by bars with a
height corresponding to the area of the growth inhibition zone.
doi:10.1371/journal.pone.0173559.g002
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eradication) to the fraction 31. At the same time, fractions 22–27 and 38–39 active in solid
growth inhibition assay did not show evidential activity against E. coli biofilm.
Experiments with S. aureus 203 biofilm revealed strong cell killing activity in fractions 28
and 29 (94 and 91% suppression compared to inactive fractions, respectively) and biofilm
eradicating activity in fractions 28–30 (83 to 74%). The optical density of the inactive fractions
in the TTC and crystal violet assays was, respectively, 1.3 ± 0.04 AU540 nm (σ = 0.244) and
1.26 ± 0.04 AU570 nm (σ = 0.259). These values in active fractions are far beyond 3 σ threshold
of inactive fractions and cannot be explained by random variation. Comparison of mean
values of anti-biofilm active (0.1 ± 0.02 and 0.29 ± 0.037 for TTC and crystal violet assays,
respectively) and inactive fractions confirms the statistical significance of these differences
(P<0.001). Fractions 26, 27 and 31–37, although they showed residual activity on planktonic
culture, have no effect on the state of S. aureus biofilm.
Mass spectrometric identification of FLIP7 anti-biofilm compounds
The fractions 26, 28–34 exhibiting anti-biofilm activity in TTC and/or crystal violet assays
were further analyzed by electrospray mass spectrometry and the masses obtained were com-
pared with the masses of known C. vicina AMPs (Table 5). Fractions 25–26 were found to con-
tain the peptide with mass identical to domesticin-like peptide. Fractions 28 and 29 were
found to contain, besides other compounds, proline-rich peptide (2987 Da) and defensin
(4032 Da) and demonstrated high cell killing and biofilm eradicating activities both against E.
coli and S. aureus biofilms, particularly fraction 28. Fraction 30 contained two masses corre-
sponding to the masses of previously sequenced C. vicina diptericin AMPs. This fraction
exhibited maximal cell killing and biofilm eradicating activity against E. coli and moderate
Table 4. Cell killing (TTC assay) and biofilm eradicating (crystal violet assay) activity of FLIP7 fractions against E. coli and S. aureus biofilms.
Fraction№ S. aureus E. coli
TTC Crystal violet TTC Crystal violet
OD %* OD %* OD %* OD %*
22 1.28 1.09 0.77 1.29
23 1.44 0.99 0.84 1.11
24 1.38 0.85 0.71 0.93
25 1.54 1.08 0.45 64 0.96
26 1.44 1.14 0.46 66 0.74
27 1.44 0.81 0.70 0.74
28 0.08 6 0.22 17 0.05 7 0.17 14
29 0.12 9 0.33 26 0.30 43 0.24 20
30 0.75 0.33 26 0.09 13 0.14 11
31 1.96 1.07 0.24 34 0.12 10
32 1.32 0.57 0.03 4 0.29 24
33 1.09 0.62 0.41 59 0.39 32
34 1.21 1.10 0.47 0.44 36
35 1.23 1.15 0.47 1.26
36 1.30 1.17 0.47 0.72
37 1.39 0.56 0.56 0.56
38 1.53 0.73 0.62 0.73
39 1.45 1.10 0.62 1.10
*% of the mean level of inactive fractions
doi:10.1371/journal.pone.0173559.t004
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biofilm eradicating (but not cell killing) activity against S. aureus. Fractions 33–34, among
other compounds, contained the mass 4156 Da precisely corresponding to the mass of cecro-
pin, previously sequenced C. vicina AMP. Fractions 31–32 did not contain any known C.
vicina AMPs although demonstrated anti-E. coli (but not anti-S. aureus) activities. The fraction
31 contained three groups of materials with masses noted in the Table 5. The fraction 32 con-
sisted of solely one group, which is characterized by masses similar or identical to only one
group of the materials from fraction 31. So, fractions 31 and 32 seem to contain a novel group
of AMPs. It is notable that fraction 31 demonstrated predominantly cell eradicating activity in
contrast to the fraction 32 having mainly cell killing activity. This fact points to the presence of
at least two compounds with complementary anti-biofilm activity.
Transcriptomic analysis of C. vicina AMPs
In addition to the above mass spectrometric analysis of the maggots AMPs, their composition
was further analyzed by transcriptome analysis as described in Materials and Methods. The
transcriptome data are available at https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=
search_obj (submission number SRR5210297). The database of the mRNAs containing 1.1
million entries was screened using sequences of known C. vicina AMPs as a query. Table 6
summarizes major findings of the database analysis. The analysis revealed two sequences
named here defensin 1 and defensin 2 identical to C. vicina [35] and Lucilia sericata [47]
defensins. In addition, we found one sequence identical to cecropin and a wide variety of
sequences with a high level of similarity with diptericins and proline-rich peptides previously
isolated from the hemolymph of C. vicina [30, 35]. Poole of proline-rich peptides include 47
sequences with similarity level of 82–86% from the previously sequenced peptide (P<0.001).
Diptericin-like peptides are present by 385 sequences with similarity level 70–82% to previ-
ously sequenced diptericin. Therefore, Table 6 contains only a small fraction of the likely
diversity of diptericins and proline-rich peptides.
Table 5. Mass spectrometric characteristics and activity profiles of FLIP7 anti-biofilm AMPs.
Fraction AMPs Molecular masses, Da Relative anti-biofilm activity1
Found in the sample Masses of known peptides E. coli S. aureus
TTC Crystal violet TTC Crystal violet
25–26 4442.2 4442.2 (domesticin-like peptide)2 + - - -
28 2986.7 +++ +++ +++ +++
4032.5 2987.0 (P-rich)3
29 2986.7 4032.0 (defensin)3 + ++ +++ ++
4032.5
30 8886.2 8886.2 (diptericin)3 +++ +++ - ++
8999.4 8999.7 (diptericin)3
31 3483–3631 + +++ - -
6773–6973 Not found
8468
32 6773–6798 +++ + - -
33 4156 4156.0 (cecropin)3 + + - -
34 4156 - + - -
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FLIP7 cytotoxicity to human blood cells
Flow cytometry cytotoxicity assay based on the differential count of necrotic (propidium
iodide positive, annexin V negative) and apoptotic (annexin V positive) cells incubated 12
hours in the cell culture medium supplemented with FLIP7 confirmed absence of the AMP
complex direct toxicity to human peripheral blood lymphocytes and monocytes (Table 7).
Number of necrotic lymphocytes and monocytes remained at the level of control variant.
ANOVA test also revealed no significant effect on the amount of necrotic lymphocytes and
monocytes in the whole range of concentrations according to P values represented in the table.
The number of annexin V positive cells in the lymphocyte population did not reveal a signifi-
cant FLIP7 impact as well. However, in the population of monocytes FLIP7 at concentration
10 mg/mL caused a significant increase of apoptotic cells number compared to control
(P = 0.004). ANOVA test confirms a significant FLIP7 effect on the monocytes’ apoptosis in
the studied concentration range.
Discussion
Results of the study of C. vicina AMP complex presented in this article clearly demonstrate the
complex activity against established antibiotic resistant biofilms formed by human pathogenic
E. coli, S. aureus and A. baumannii. However, the biofilms’ resistance growth over planktonic
Table 6. Sequences of C. vicina AMPs determined by transcriptome analysis and peptide sequencing.





Defensin 1 C0HJX7 ATCDLLSGTGANHSACAAHCLLRGNRGGYCNGKAVCVCRN + +1
Defensin 2
(Lucifensin-II)
B3EWY5 ATCDLLSGTGIKHSACAAHCLLRGNRGGYCNGRAICVCRN + -
Cecropin C0HJX8 GGWLKKIGKKIERVGQHTRDATIQGLAVAQQAANVAATAR + +1
Diptericin 1 C0HJX9 DSKPLNLVLPKEEPPNNPQTYGGGGGSRKDDFDVVLQGAQXEV. . .(N-terminal) - +1
Diptericin 2 QNKPFKLTLPKEEPKNLPQLYGGGGGSRKQGFDVSLGAQQKVWESQNKRHSVDNAGY + -
P-rich 1 C0HJY0 FVDRNRIPRSNNGPKIPIISNP. . .(N-terminal) - +1
P-rich 2 FVDRSRRPNSNNGPKIPIISNPPFNPMPDLPGRE + -
P-rich 3 FVDRSRRPNSNNGPKIPIISNPPFNPNARPAW + -







Table 7. Numbers (mean ± standard error) of apoptotic (annexin V positive) and necrotic (propidium iodide positive, annexin V negative) human
peripheral blood leukocytes per 100 gated cells after in vitro incubation with FLIP7.
FLIP7, mg/mL Lymphocytes Monocytes
Apoptotic Necrotic Apoptotic Necrotic
0 2.5 ± 0.8 0.40 ± 0.136 26.8 ± 5.50 0.57 ± 0.180
0.5 2.2 ± 0.69 0.31 ± 0.139 27.5 ± 6.28 0.38 ± 0.103
5 2.2 ± 0.40 0.76 ± 0.263 40.4 ± 12.70 0.31 ± 0.077
10 3.5 ± 0.84 0.46 ± 0.183 71.7 ± 10.91 0.23 ± 0.049
P 0.817 0.384 0.009 0.207
doi:10.1371/journal.pone.0173559.t007
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cells’ level considerably depends on the bacterial species. The growth quantified by MBIC90/
MIC ratio is negligible in S. aureus (from zero to twofold), moderate (three to tenfold) in E.
coli and significant (18 to 51-fold) in A. baumannii strains. Nevertheless, increase of the bio-
films resistance to the range of reference antibiotics in most cases was significantly higher (24
to 667-fold) than the complex values. FPL7 activity is mostly attractive in its MBEC/MIC ratio
rather than on its absolute MIC value, in comparison to standard antibiotics. Another key
advantage of the complex is its ability to block resistance development in Gram-negative bacte-
ria [30]. Equally important is the fact that the complex is active against both planktonic and
biofilm forms of bacteria. Since each bacterial infection is initiated by free-living cells and in
most cases goes to form biofilms, it allows the complex to control different stages of disease
development. The complex anti-biofilm activity involves two coordinated processes: cells kill-
ing and matrix degradation that occur at the same threshold concentrations of the complex
and, therefore, may prevent the spread of surviving bacteria beyond the hotbed of infection
after the destruction of the matrix.
To perform its anti-biofilm function, the complex operates with at least five fully sequenced
peptides named in this paper as Calliphora defensin 1, cecropin, diptericin 1, P-rich 1 and
domesticin-like peptides (Table 6). The same AMPs were identified in C. vicina using plank-
tonic bacteria as a test system [30, 35,36]. Diptericin 1 had previously been only partially
sequenced, now its complete sequence is available. Moreover, the data obtained demonstrated
the presence of some additional anti-E. coli AMPs, which remain to be structurally character-
ized. Thus, the complex comprises at least 7 AMPs synthesized and accumulated in the mag-
gots’ hemolymph in response to bacterial infection (Table 5). Sequenced peptides belong to
four families of cationic AMPs: defensins, cecropins, diptericins and proline-rich peptides,
respectively. Defensins, cecropins and proline-rich peptides are widely distributed and well-
studied insect AMPs [17, 18]. Defensins are a group of AMPs containing α-helix/β-sheet ele-
ments coordinated by three disulfide bridges and known to be selectively active against Gram-
positive bacteria. Cecropins are linear amphipathic α-helical AMPs selectively active against
Gram-negative bacteria. Diptericins are members of glycine-rich AMP family selectively toxic
to some Gram-negative Enterobacteria like E. coli by means of cell wall disruption [38]. C.
vicina proline-rich peptides belong to the group of proline/arginine-rich AMPs, which are
known to kill bacteria by damaging DNA and/or protein synthesis [39]. Thus, C. vicina AMP
complex comprises three structurally distinct groups of cell wall disrupting AMPs targeted
predominantly to the membranes of Gram-negative (cecropins, diptericins) or Gram-positive
(defensins) bacteria and one group affecting intracellular targets (proline/arginine rich
peptides).
Bioassays of the complex chromatographic fractions indicated that all found AMP families
possess anti-biofilm activity of two types: cell killing (determined by TTC assay) and matrix
destroying (determined by crystal violet assay). However, the proportions of these effects as
well as activity against biofilms formed by different types of bacteria are characteristic for each
family. Chromatographic fractions containing defensin 1 and P-rich 1 peptides provided the
bulk of anti-staphylococcal activity and significant part of anti-E. coli activity. Cecropin, dip-
tericin and domesticin-like peptide fractions as well as unidentified AMPs were selectively
active against E. coli but not S. aureus biofilms. The diverse composition of the AMPs toxic to
E. coli corresponds to the mass dissemination of Enterobacteria and related Gram-negative
species in C. vicina natural habitats.
Analysis of the composition of C. vicina AMPs demonstrates sophisticated nature of this
defense system. In reality it may be even more intricate. Transcriptome analysis revealed about
500 mRNA isoforms encoding sequences of all four AMP families. Of this amount, diptericins
family contains not less than 385 mRNAs comprising motif of five glycine residues typical to
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insect diptericins and demonstrating 70–82% sequence similarity with previously sequenced
C. vicina diptericin 1. Not all detected mRNAs lead to AMPs. For example, we have found in
C. vicina mRNA encoding lucifensin-II, defensin from another blowfly species Lucilia sericata
[47] but did not find the peptide itself. There is little doubt that many other AMP-encoding
mRNAs also remain "silent" as it was demonstrated in some insects [29, 48]. Others may
encode peptides having no antimicrobial activity. Nevertheless, we cannot exclude that the
complex comprises more AMPs than found today.
AMPs are regarded as promising drug candidates for the treatment of biofilms [31–33].
According to data presented in this article, C. vicina defensins, diptericins, cecropins and pro-
line-rich peptides can be added to this list. However, nature seems to be not in vain using
multi-component complexes instead of single AMPs. In addition to the above-mentioned
advantages, it allows the immune system to explore synergistic activity of various AMPs. The
synergy is described repeatedly in the literature with regard to the combination of two [27–29]
or three [49] AMPs. An analysis of more complex combinations remains a formidable task.
No less important is the fact that the resulting synergistic combination must possess a number
of other qualities to become a medicine. This makes the development of therapeutic AMP
combinations extremely difficult. The study of the natural AMP complexes can be very helpful
in solving this problem. Particularly promising from this point of view are AMP complexes of
C. vicina and other blowflies living in environments with the highest concentration of human
pathogenic microflora [25]. Besides the information about the structure and properties of the
antimicrobial compositions withstood rigorous and impartial examination by natural selec-
tion, the larvae of C. vicina can supply the necessary components for their production. Meth-
ods of in situ and in vitro biosynthesis of C. vicina AMP complex make it technically and
economically feasible [25, 36]. In future, this and similar natural AMP complexes can be
applied in various fields of medicine, from routine bacterial infections to chronic inflamma-
tory diseases and cancer. The most promising is their use for the treatment and prevention of
diseases caused by antibiotic-resistant biofilms.
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